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OBJECTIVES: In the Arimidex, Tamoxifen Alone or in combi-
nation (ATAC) trial, anastrozole produced signiﬁcantly longer
disease-free survival and time to recurrence compared with
tamoxifen in postmenopausal women with hormone receptor-
positive (HR+) early breast cancer after 5 years of treatment
(ATAC Trialists’ Group. Lancet 2005;365:60–2). A cost-effec-
tiveness analysis of anastrozole compared with generic tamox-
ifen was undertaken for inclusion in a submission to the
Australian Pharmaceutical Beneﬁts Advisory Committee (PBAC)
seeking national reimbursement for anastrozole in early breast
cancer. METHODS: A Markov model and Weibull survival
curves ﬁtted to trial data were used to project 5-year outcomes
from the ATAC trial to an actuarial time point of 20 years (a
conservative lifetime equivalent). Resource utilisation data were
obtained from a survey of Australian physicians and the pub-
lished literature. Unit costs (2003–4 AU$) were obtained from
routine sources. A societal perspective was adopted although
indirect costs were not included. Utility scores, derived from a
study in postmenopausal women with early breast cancer, were
incorporated into the model. Costs and beneﬁts were discounted
at the annual rate of 5%. Incremental cost effectiveness ratios
(ICERs), 95% CIs, and acceptability curves were calculated.
RESULTS: The ICERs and 95% CIs for anastrozole compared
with tamoxifen at 20 years were AU$28,532 (AU$16,146–
AU$65,500) per life year gained and AU$24,113 (AU$13,170–
AU$59,357) per QALY gained. There was a greater than 90%
probability that the cost per QALY gained with anastrozole
would be lower than AU$50,000. The results were sensitive to
the time horizon of the model and the assumptions about the
duration of treatment beneﬁt. CONCLUSIONS: Compared with
thresholds accepted in Australia for new drug entities, anastro-
zole is a cost-effective alternative to generic tamoxifen for
primary adjuvant treatment of postmenopausal women with
HR+ early breast cancer.
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OBJECTIVES: NICE Guidance in 2001 recommended vinorel-
bine, paclitaxel, and gemcitabine as part of ﬁrst-line chemother-
apy options for NSCLC patients. Since the Guidance was
published, an oral formulation of vinorelbine and docetaxel has
been introduced in UK. A Markov model has been developed to
realise an indirect comparison of these ﬁve chemotherapies, and
deﬁne their respective level of costs in the NHS’ perspective.
METHODS: Thirteen commonly used regimens including the
oral form with an administration in d8 at home were deﬁned by
a panel of clinical oncologists. In absence of signiﬁcant statisti-
cal difference between the principal criteria of effectiveness, a
cost-minimization study was carried out by allocating to all com-
parators the published data for vinorelbine in Le Chevalier 1999.
The corresponding unit costs of drugs, administration and toxi-
city management, patient transportation costs were gathered
from BNF, PSSRU. The main cost incurring toxicities based on
occurrence in referenced publications were taken into account.
RESULTS: With the conservative assumption of no differences
in therapeutic efﬁcacy, the oral vinorelbine at a dose of 60
mg/m2/week, with one week of rest every 3 weeks, appears as
the least expensive strategy: with an administration in d8 at
home under a general practitioner supervision, its annual follow-
up cost is of £2888; with an outpatient visit in d8, its annual
cost is of £3448. Administrated within a day-hospitalization,
intravenous vinorelbine 25mg/m2 d1 d8, gemcitabine 1250
mg/m2 d1, d8, paclitaxel 175mg/m2 and docetaxel 100mg/m2
incur annual follow-up costs respectively of £3746, £5332,
£5977 and £6766. The oral vinorelbine allows savings of £858
compared to its intravenous form, £2444 compared to gemc-
itabine, £3089 and £3878 compared to paclitaxel and docetaxel
per patient managed for one year. CONCLUSION: Oral vinorel-
bine has a less budgetary impact due to the reduction of the hos-
pital expenditure.
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OBJECTIVES: To evaluate cost of colorectal cancer chemother-
apies (i.e. AIO/Ardalan-regime, Mayo Clinic protocol and oral
capecitabine) in different treatment settings (private ofﬁce, hos-
pital) considering recent changes in drug costs and payment
mechanisms in Germany. METHODS: Resource utilization 
data, derived from 89 quarterly fee-listings for patients with
metastatic colorectal cancer, were re-analyzed using the new
EBM2000plus tariff system (introduced April 05) for ofﬁce-
based physicians, the 2005 DRG-System for hospital treatment
and new regulation on drug prices according to the 2004 health
care reform. Physician’s services, drug costs, pharmacy costs and
costs for implantable venous port systems and single-use pumps
were considered. Several scenarios to reﬂect different assump-
tions were calculated. A third party payer perspective (statutory
sickness funds) was adopted. RESULTS: Depending on the treat-
ment setting (ofﬁce-based, municipal hospital, university hospi-
tal), quarterly treatment costs for the AIO/Ardalan-regimen
varied between €5412 and €15,109, and for the Mayo-Clinic
protocol between €2602 and €4751. Projected costs for
capecitabine were €1980. No hospitalisation was considered to
be necessary for capecitabine due to its oral route of adminis-
tration. Projecting these cost differences to epidemiological data
and treatment pattern information results in a yearly savings
potential of €117 Mio—€214 Mio (depending on assumptions
on hospital care pattern) for German statutory sickness funds by
switching these patients to capecitabine treatment. Compared to
the original analyses, based on cost and payment mechanisms
from 2000, substantial differences were observed. CONCLU-
SION: Treatment using the AIO/Ardalan-protocol was clearly
the most expensive treatment option, treatment using
capecitabine incurred lowest costs. Substantial cost-savings for
sickness funds could be achieved if more patients were treated
with capecitabine. Recent changes in German payment mecha-
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nisms had a substantial impact on the results of health economic
evaluations.
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OBJECTIVES: Follicular non-Hodgkin’s lymphoma (FL) is the
most common indolent lymphoma occurring in the Western
Hemisphere with a variable clinical course. Because of high costs
of new treatments, we assessed direct health care costs associ-
ated with the most commonly prescribed treatments for FL.
METHODS: New and previously diagnosed FL patients (>18
years) known during 1997–1998 to 15 Dutch hospitals were ran-
domly selected for inclusion. Each patient was followed for three
years, from a distinct event in the disease course onwards, for
resource use associated with each of the treatments, including
‘watchful waiting’. The hospital perspective was adopted. Unit
costs were based on the 2003 price level. RESULTS: Two
hundred patients were included, of whom 75% percent under-
went >1 treatment during the 3-year data collection period (25%
was not treated because of a watchful waiting strategy (10%) or
complete remission (15%)). Allogeneic and autologous stem cell
transplantations were the most expensive treatments, with a
mean per patient cost of €45,326 (n = 7) and €18,866 (n = 9)
respectively (up to discharge only). This was followed by ﬂu-
darabine i.v. €10,651 (n = 33), rituximab (€10,628; n = 7), and
CHOP €7547 (n = 42). Classical FL treatments were found to
be the least expensive treatments used with an estimated cost for
CVP of €5268 (n = 58), for radiotherapy of €4218 (n = 52), and
for chlorambucil of €2476 (n = 53). CONCLUSIONS: This study
presents detailed information on resource use and costs associ-
ated with the most commonly prescribed FL treatments. In addi-
tion to differences in effectiveness, commonly used treatments
vary considerably in terms of resource use and overall cost. This
information is of value for resource planning.
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ECONOMIC ASPECTS AND DRIVERS OF FEBRILE
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RETROSPECTIVE ANALYSIS IN BELGIUM
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OBJECTIVES: To determine costs and identify cost drivers for
febrile neutropenia (FNE) in Belgium. METHODS: Direct costs
of FNE to health care payers were calculated from retro–pro-
jected chart review of patients treated during 2003 in 4 centres
(n = 93, 4 Hodgkin’s disease (HD), 36 Non–Hodgkin lymphoma
(NHL), 10 multiple myeloma, 35 breast cancer (BRCA) and 8
small–cell lung cancer). Clinical data and FNE related resource
utilization were collected from patient ﬁles. Cost data included
all FNE related costs. Resource use (including hospitalisation,
antimicrobials, perfusions, lab tests, interventions and other
drugs) was multiplied with unit costs from ofﬁcial sources.
Regression analysis to identify cost drivers was performed on
log–transformed costs using a mixed linear model. RESULTS:
The average number of FNE’s in patients with FNE was 1.3, the
ﬁrst FNE occurring after 1.7 cycles. The average number of
FNE’s tended to be higher in patients with hematological malig-
nancies and in patients receiving combination chemotherapy.
The mean cost per FNE episode, excluding G–CSF treatment and
secondary prevention, was €4221 (95% CI:3521–4921). Major
cost components were hospitalization (€2707), antimicrobial
therapy (€784) and tests (€636). Growth factors were prescribed
for FNE treatment and secondary prevention in 84% and 51%
of patients respectively. The average total cost of growth factors
was €2197. Mortality during chemotherapy was 11%. Regres-
sion analysis showed that underlying disease and survival were
independent cost drivers. NHL patients incurred 1.85 times
higher costs than others (95% CI:1.07–3.20, p = 0.0316).
Patients who died, either from FNE or from their underlying
disease, showed 1.52 times higher costs (95% CI:1.04–2.22, p =
0.0347) than survivors. Co–existence of thrombocytopenia or
anemia also signiﬁcantly predicted higher FNE costs. CON-
CLUSION: The cost of FNE varied according to underlying
disease. NHL patients showed the most elevated total FNE
related costs. These analyses of cost drivers enable to ﬁne–tune
data for economic analyses to relevant patient subgroup.
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OBJECTIVES: To estimate cost associated with informal care
giving in advanced stage Non-Small Cell Lung Cancer (NSCLC)
patients, identifying the costs drivers in Italy; to measure symp-
toms evolution using the LCS subscale of the FACT-L question-
naire. METHODS: A total of 104 patients (55 on second line
chemotherapy and 49 in supportive care) were enrolled in 18
Italian oncology departments and followed up for 3 months.
Main caregiver workload was assessed monthly by evaluating
the number of hours devoted to ten care giving tasks, presence
and activities of other informal or formal caregiver were regis-
tered, performance status was evaluated monthly by means of
the ECOG scale. Patients completed the LCS symptoms subscale
for each visit. Formal care giving time was valued according to
market prices; informal care giving hours were valued using the
wage rate for an equivalent service. The covariance analysis was
performed to check for inﬂuential factors in assistance need and
costs. RESULTS: During the 3-month observational period both
ECOG and LCS scores depreciated in the two groups. An equal
number of deaths were registered among patients in chemother-
apy and in supportive care. Monthly hours of informal care
giving increased from 124.37 to 166.9 for the chemotherapy
patients and from 141.92 to 150.97 for supportive care patients.
The whole home assistance cost accounted for €3159 for
chemotherapy and €4189 for supportive care patient. The regres-
sion analysis highlighted that symptom depreciation is a driver
of care giving time and costs and that the assistance cost
increases if the caregiver doesn’t live with the patient. CON-
CLUSIONS: The burden of assistance in NSCLC advanced
patients is mainly beard by family members who provide also
home health aide. As the population ages and family structure is
changing, social intervention targeted at unpaid family caregiver
will be needed to ease the economic, psychological and physical
burden of care giving.
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